Steven George Hughes
Chief Medical OfficerDr. Steven George Hughes, also known as Steve, MBA, MD, is Chief Medical Officer of Atrium Therapeutics, Inc. He served as Chief Medical Officer at Avidity Biosciences, Inc. since February 2022 until February 27, 2026. He joined Avidity Biosciences, Inc. in February 2022. He has a unique combination of extensive experience in the RNA field as well as a deep understanding of rare disease drug development. He has experience of building and leading clinical development and medical affairs teams at prominent biopharmaceutical companies. He served as Chief Medical Officer of Arcturus Therapeutics Holdings Inc until February 14, 2022 and served as its Chief Development Officer since January 2, 2020. He serves as Strategic Clinical Advisor at Arcturus Therapeutics Holdings Inc. since February 14, 2022 and serves as its Member of Scientific Advisory Board since March 2022. Dr. Hughes was Chief Medical Officer of Organovo Holdings, Inc. since August 1, 2018 until August 30, 2019. He was Chief Clinical Development Officer at Ionis Pharmaceuticals since 2018 and has extensive experience in the pharmaceutical and biotech industry. He was responsible for oversight of all stages of clinical development of Ionis antisense drugs. Since joining Ionis in 2011, he has been involved in more than 50 clinical trials with more than 25 drugs across multiple therapeutic areas, including cardiovascular, metabolic, neurology, oncology, infectious diseases, rheumatology, ophthalmology and rare diseases, in the U.S. and other regions. He has been closely involved in multiple registrational regulatory filings, including playing a key role in the approval of three rare disease products in the last six years. He has also played a key role in the submission of three NDA/MAA applications. Dr. Hughes has an extensive and successful record of accomplishment of progressing innovative therapeutic opportunities from the preclinical stage through to commercialization. Prior to joining Ionis, he worked at Sanofi, CSL Behring and Biogen Idec where he was the global medical lead for several oncology drugs in Phase 1 to 3 clinical development. He received his medical degree from Imperial College, London and has an MBA with distinction from Imperial College Business School. He is Board certified in pharmaceutical medicine.
Positions
- Company NameAtrium Therapeutics, Inc.Stock CodeRNAPositionChief Medical OfficerColleagues
- KPKathleen P. GallagherPresident, CEO & Director
- SBSarah BoyceIndependent Chair of the Board of Director
- BWBrendan WinslowChief Financial Officer
- HYHusam YounisChief Scientific Officer
- SKStephanie KenneyChief Corporate Affairs Officer
- CBCarsten BoessIndependent Director
- TETroy Edward WilsonIndependent Director
- WMW. Michael F. FlanaganIndependent Director
